Croissance économique et productivité

Le sous-thème Croissance économique et productivité traite de la relation entre les maladies évitables par la vaccination ou la vaccination et la productivité et la croissance économique au niveau de la population. La productivité est une mesure de la production d’un individu actif ou d’une population dans son ensemble. C’est le déterminant le plus important du niveau de vie d’un groupe de personnes ou d’une nation.

5 Key Concepts

Key Evidence: Children hospitalized with rotavirus in Norway were absent from daycare for 6.3 days, on average, and 73% of their parents missed work -- for a mean of almost 6 days. These data, which can be used in economic evaluations of rotavirus vaccination, show that work absenteeism resulting from having a child hospitalized with rotavirus poses a considerable economic burden on society.

View Publication >

Key Evidence: In the mid-1980s, the Indian government examined the effect of their universal immunization program on child mortality and educational attainment. Results indicate that exposure to the program reduced infant mortality by 0.4 percentage points and under five child mortality by 0.5 percentage points. These effects on mortality account for approximately one-fifth of the decline in infant and under five child mortality rates between 1985-1990. The effects are more pronounced in rural areas, for poor people, and for members of historically disadvantaged groups.

View Publication >

Key Evidence: In a study of immunization in the Philippines, children vaccinated against 6 diseases performed significantly better on verbal reasoning, math, and language tests than those who were unvaccinated. (note: Researchers did not find an association with physical growth.)

View Publication >

Key Evidence: A study of the economic burden of cholera in Africa found that 110,837 cases of cholera reported in 2007 resulted in an economic loss of $43.3 million, $60 million and $72.7 million US dollars, assuming life expectancies of 40, 53 and 73 years respectively.

View Publication >

Key Evidence: Researchers modeled the costs, using the UK’s 2004 economy, of potential pandemic flu in the UK. Costs of illness alone ranged between 0.5% and 1.0% of gross domestic product (£8.4bn to £16.8bn) for low fatality scenarios, 3.3% and 4.3% (£55.5bn to £72.3bn) for high fatality scenarios, and larger still for an extreme pandemic. Vaccination with a pre-pandemic vaccine could save 0.13% to 2.3% of gross domestic product (£2.2bn to £38.6bn); a single dose of a matched vaccine could save 0.3% to 4.3% (£5.0bn to £72.3bn), and two doses of a matched vaccine could limit the overall economic impact to about 1% of gross domestic product for all disease scenarios.

View Publication >

Key Evidence: For every 6 children vaccinated against measles in a poor, largely rural community in South Africa, one additional grade of schooling was achieved.

View Publication >

Key Evidence: In 1996, a follow-up study was conducted on a 1974 randomized trial of tetanus and cholera vaccine administered to mothers. At the time of follow up in 1996, there was a clear pattern of increased educational attainment among children whose mothers received tetanus vaccine during pregnancy. This pattern was significant for the group of children born to vaccinated mothers with very low levels of education.

View Publication >